Related Experiment Video

Updated: Jun 2, 2026

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load

Stéphane De Wit1, Marc Delforge, Coca Valentina Necsoi

  • 1Division of Infectious Diseases, Saint-Pierre University Hospital, Brussels, Belgium.

AIDS (London, England)
|April 22, 2011
PubMed

Insights

Atorvastatin significantly reduced immune activation, measured by CD38, in HIV patients with undetectable viral loads. This study suggests a potential benefit of statins in managing chronic inflammation during HIV disease.

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • Chronic inflammation and immune activation persist in HIV patients even with suppressed viral loads.
  • These factors contribute to the long-term complications of HIV disease.
  • CD38 activation is a marker of immune activation relevant to HIV pathogenesis.

Purpose of the Study:

  • To investigate the impact of atorvastatin on CD38 activation in HIV patients with undetectable viral loads.
  • To assess whether atorvastatin influences other markers of inflammation and immune status.

Main Methods:

  • A case-control study was conducted with 133 cases and 266 controls.
  • Patients had undetectable viral loads.
  • CD38 activation, high-sensitivity C-reactive protein (hsCRP), and CD4 counts were measured at week 48.

Main Results:

  • CD38 activation levels were significantly lower in the atorvastatin group (cases) compared to the control group at week 48.
  • No significant differences were observed in high-sensitivity C-reactive protein (hsCRP) or CD4+ T-cell counts between the groups.
  • The findings indicate a specific reduction in immune activation.

Conclusions:

  • Atorvastatin effectively reduces immune activation, as indicated by lower CD38 expression, in HIV patients with suppressed viremia.
  • The drug did not significantly alter hsCRP or CD4 counts in this cohort.
  • These results suggest atorvastatin may be a valuable therapeutic option for managing immune activation in HIV.

More Related Videos

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals06:46

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals

Published on: January 5, 2016

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...